Following closure of an oversubscribed first round, AxioMed opened a US $10MM round of funding to support operations and ex-U.S. sales.
In 1Q17, the company completed collection and analysis of 2-year follow-up data in its U.S. Investigational Device Exemption (IDE) clinical study of its viscoelastic lumbar disc. AxioMed expects 1Q18 CE Mark approval for its lateral disc, and is pursuing a multi-level cervical IDE in the U.S.
Sources: AxioMed; ORTHOWORLD Inc.
Following closure of an oversubscribed first round, AxioMed opened a US $10MM round of funding to support operations and ex-U.S. sales.
In 1Q17, the company completed collection and analysis of 2-year follow-up data in its U.S. Investigational Device Exemption (IDE) clinical study of its viscoelastic lumbar disc....
Following closure of an oversubscribed first round, AxioMed opened a US $10MM round of funding to support operations and ex-U.S. sales.
In 1Q17, the company completed collection and analysis of 2-year follow-up data in its U.S. Investigational Device Exemption (IDE) clinical study of its viscoelastic lumbar disc. AxioMed expects 1Q18 CE Mark approval for its lateral disc, and is pursuing a multi-level cervical IDE in the U.S.
Sources: AxioMed; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.